Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taligen Therapeutics has announced that it expects to receive up to $65 million in a tranched series B financing.
Subscribe to our email newsletter
The financing was led by Alta Partners and Clarus Ventures with participation from existing investors, including Sanderling Ventures, Tango and High Country Venture.
Timothy Mills, chairman of the board of Taligen, said: “With this additional funding, we expect to move into clinical development with all of our lead candidates.”